Avidity Partners Management LP An2 Therapeutics, Inc. Transaction History

Avidity Partners Management LP

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$2.78 - $21.53 $27,799 - $215,300	10,000 Added 0.88%	1,150,000 $3.74 Million
Q4 2023 Feb 14, 2024	BUY	$13.92 - $21.0 $704,352 - $1.06 Million	50,600 Added 4.64%	1,140,000 $23.4 Million
Q3 2023 Nov 14, 2023	BUY	$7.58 - $16.08 $3.28 Million - $6.95 Million	432,200 Added 65.76%	1,089,400 $17.5 Million
Q2 2023 Aug 14, 2023	SELL	$5.06 - $9.91 $333,960 - $654,060	-66,000 Reduced 9.13%	657,200 $5.59 Million
Q1 2023 May 15, 2023	SELL	$7.94 - $15.6 $161,976 - $318,240	-20,400 Reduced 2.74%	723,200 $7.14 Million
Q4 2022 Feb 14, 2023	BUY	$8.51 - $19.69 $8,254 - $19,099	970 Added 0.13%	743,600 $7.09 Million
Q3 2022 Nov 14, 2022	BUY	$7.61 - $22.29 $413,223 - $1.21 Million	54,300 Added 7.89%	742,630 $12.9 Million
Q1 2022 May 16, 2022	BUY	$15.0 - $15.4 $10.3 Million - $10.6 Million	688,330 New	688,330 $10.4 Million

13.5M

Ticker ANTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 19,402,700
Market Cap $20.8M
Description
AN2 Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for rare, chronic, and serious infectious diseases. It is developing epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial lung disease. The company was incorporated in 2017 and is headquartered in Menl...

Get notified when there are updates to the investment portfolio of Avidity Partners Management LP, based on Form 13F filings with the SEC.

Stay updated on Avidity Partners Management LP with notifications on news.